(Total Views: 597)
Posted On: 12/03/2024 9:09:59 PM
Post# of 148870
Dr. RP clarity:
7.9 Sponsored Research Agreements.
Schedule 7.9 sets forth (a) the remaining funds payable to Blumberg by Seller for “Year 1” (the “Remaining Payment”) under the 2018 Animal Research Agreement and (b) the remaining costs payable to Blumberg for “Year 2” and “Year 3” under the 2018 Animal Research Agreement (the “Remaining Cost”). Prior to the Closing, Seller shall pay the Remaining Payment to Blumberg and enter into a Research Plan under the Master Blumberg SRA, in form and substance reasonably acceptable to the Company, which shall clarify that all research performed by Seller under the Animal Research Agreements has been performed under the Master Blumberg SRA (the “Research Plan”). The Research Plan shall provide for additional research to be performed by Blumberg as contemplated for “Year 2” and “Year 3” under the 2018 Animal Research Agreement, at the Remaining Cost, upon terms and conditions substantially similar to the terms and conditions of the 2018 Animal Research Agreement. For the avoidance of doubt, at the Closing, the Master Blumberg SRA and the Research Plan will be assumed by the Surviving Corporation pursuant to an Assignment and Assumption Agreement as set forth in this Agreement."
__
His detection kit was designed in 2018, collab with Baruch S. Blumberg Institute .
Baruch 2018 ranked 2nd in country & is tied to Pennsylvania Cancer
Test kit was a 3 year follow-up to 10 years of testing data, per Cytodyn news release on Pestell joining.
Cytodyn bought it @ year #1.
Pestell paid Brauch to do the remaining 2 years of testing for Cytodyn.
So how was he responsible?
I could care less about Pestell, but shareholders should know "he" didn't "knowingly" sell a test kit that didn't work or here to "steal".
To me, good thing having got Pestell to drop defamation suit & it all boils down to because of the known power to be released by LL, working together.
How the hell is this a .12 cent stock
7.9 Sponsored Research Agreements.
Schedule 7.9 sets forth (a) the remaining funds payable to Blumberg by Seller for “Year 1” (the “Remaining Payment”) under the 2018 Animal Research Agreement and (b) the remaining costs payable to Blumberg for “Year 2” and “Year 3” under the 2018 Animal Research Agreement (the “Remaining Cost”). Prior to the Closing, Seller shall pay the Remaining Payment to Blumberg and enter into a Research Plan under the Master Blumberg SRA, in form and substance reasonably acceptable to the Company, which shall clarify that all research performed by Seller under the Animal Research Agreements has been performed under the Master Blumberg SRA (the “Research Plan”). The Research Plan shall provide for additional research to be performed by Blumberg as contemplated for “Year 2” and “Year 3” under the 2018 Animal Research Agreement, at the Remaining Cost, upon terms and conditions substantially similar to the terms and conditions of the 2018 Animal Research Agreement. For the avoidance of doubt, at the Closing, the Master Blumberg SRA and the Research Plan will be assumed by the Surviving Corporation pursuant to an Assignment and Assumption Agreement as set forth in this Agreement."
__
His detection kit was designed in 2018, collab with Baruch S. Blumberg Institute .
Baruch 2018 ranked 2nd in country & is tied to Pennsylvania Cancer
Test kit was a 3 year follow-up to 10 years of testing data, per Cytodyn news release on Pestell joining.
Cytodyn bought it @ year #1.
Pestell paid Brauch to do the remaining 2 years of testing for Cytodyn.
So how was he responsible?
I could care less about Pestell, but shareholders should know "he" didn't "knowingly" sell a test kit that didn't work or here to "steal".
To me, good thing having got Pestell to drop defamation suit & it all boils down to because of the known power to be released by LL, working together.
How the hell is this a .12 cent stock
(4)
(0)Scroll down for more posts ▼
